2018
Comparison of Residual Risk–Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies
Wei W, Kurita T, Hess KR, Sanft T, Szekely B, Hatzis C, Pusztai L. Comparison of Residual Risk–Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies. JAMA Oncology 2018, 4: e175092-e175092. PMID: 29372234, PMCID: PMC5885272, DOI: 10.1001/jamaoncol.2017.5092.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantEligibility DeterminationFemaleHumansLymph NodesLymphatic MetastasisMiddle AgedNeoplasm Recurrence, LocalNeoplasm, ResidualPatient SelectionPrognosisRandomized Controlled Trials as TopicReproducibility of ResultsResearch DesignRetrospective StudiesRisk FactorsSurvival AnalysisTrastuzumabTumor BurdenWatchful WaitingYoung AdultConceptsTumor sizeAdjuvant trialsEligibility criteriaNodal statusClinical trialsResidual riskEarly-stage breast cancerAdjuvant clinical trialsBaseline prognostic riskFuture adjuvant trialsResidual risk estimatesRisk of recurrenceBreast cancer therapyRisk thresholdTrial powerClinical trial powerTrial eligibilityAdjuvant therapyCare therapyConsecutive patientsPrognostic riskPatient eligibilityTrial populationPatient cohortControl arm
2010
Use of standard markers and incorporation of molecular markers into breast cancer therapy
Kaufmann M, Pusztai L, Members T. Use of standard markers and incorporation of molecular markers into breast cancer therapy. Cancer 2010, 117: 1575-1582. PMID: 21472705, DOI: 10.1002/cncr.25660.Peer-Reviewed Original ResearchConceptsFuture clinical trialsClinical trialsBreast cancerRoutine pathological evaluationBreast cancer managementCancer Research GroupBreast cancer therapyRoutine clinical decisionImportant therapeutic targetPredictive gene signaturesPathological evaluationPatient selectionConsensus recommendationsCancer managementHeterogeneous diseaseTherapeutic targetPredictive valueBreast pathologyClinical decisionDifferent subtypesGene signatureGenomic profilingClinical levelNew molecular markersOutcome prediction
2009
From the Lab to the Clinic: Gene-Expression Profiles That Are Associated with Mek-Inhibitor Sensitivity In Vitro Are Coordinately Co-Expressed in Breast Cancer Biopsy Samples from the I-SPY Trial (CALGB 150007/150012, ACRIN 6657).
Wolf D, Das D, Lenburg M, Paquette J, Spellman P, Gray J, Gray J, Pusztai L, Symmans F, Hatzis C, Esserman L, van 't Veer L, I-SPY Investigators .. From the Lab to the Clinic: Gene-Expression Profiles That Are Associated with Mek-Inhibitor Sensitivity In Vitro Are Coordinately Co-Expressed in Breast Cancer Biopsy Samples from the I-SPY Trial (CALGB 150007/150012, ACRIN 6657). Cancer Research 2009, 69: 2042-2042. DOI: 10.1158/0008-5472.sabcs-09-2042.Peer-Reviewed Original ResearchSensitive cell linesCancer cell linesOutcome dataCell linesI-SPY 2 TRIALI-SPY 1 TRIALInitial tumor responseNeo-adjuvant chemotherapyPre-treatment biopsiesThird of patientsBreast cancer biopsy samplesDrug response predictorsBreast cancer therapyBreast cancer cell linesMEK inhibitor sensitivityExpression of genesTumor responseTherapeutic responseResponse predictorsPatientsBiopsy samplesTumor samplesPatient samplesCancer ResDrug sensitivityInhibition of Lipocalin 2 Impairs Breast Tumorigenesis and Metastasis
Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, Feig B, Zhang W, Pusztai L, Symmans WF, Wu Y, Arlinghaus RB. Inhibition of Lipocalin 2 Impairs Breast Tumorigenesis and Metastasis. Cancer Research 2009, 69: 8579-8584. PMID: 19887608, DOI: 10.1158/0008-5472.can-09-1934.Peer-Reviewed Original ResearchMeSH KeywordsAcute-Phase ProteinsAnimalsBlotting, WesternBreast NeoplasmsCell Line, TumorFemaleFlow CytometryGene Expression Regulation, NeoplasticHumansImmunohistochemistryLipocalin-2LipocalinsMatrix Metalloproteinase 9MiceMice, KnockoutNeoplasm InvasivenessNF-kappa BOncogene ProteinsReceptor, ErbB-2Reverse Transcriptase Polymerase Chain ReactionSignal TransductionConceptsLCN2 expressionBreast cancerBreast tumorigenesisMatrix metalloproteinase-9 activityTumor formationMammary tumor mouse modelMammary tumor formationMetalloproteinase-9 activityMatrix metalloproteinase-9Breast cancer therapyTumor mouse modelBreast tumor formationAkt/NFBreast cancer cellsMurine breast tumorsInhibitory monoclonal antibodiesLCN2 functionsLung metastasesLipocalin-2Metalloproteinase-9Mouse modelAggressive typeBreast tumorsKappaB pathwayMetastasis